TENX Tenax Therapeutics Inc
Company Analysis
Latest News
🟢 Tenax Therapeutics is trading 5.56% up in after-hours trading; catalyst unconfirmed
Tenax Therapeutics is trading at $2.09, up 5.56%, with no verified September 8 company announcement directly explaining the after-hours move. - Closed at...
FMR Takes 1.4% Stake in Tenax Therapeutics, Backing Phase 3 Pharma Developer
FMR LLC disclosed a 1.4% ownership stake in Tenax Therapeutics Inc. through a recent SEC Schedule 13G/A filing. Tenax Therapeutics is a development-stage...
🟢 Tenax Therapeutics is trading 10.57% up today — no clear company-specific catalyst
Tenax Therapeutics is trading at $2.15, 10.57% up on September 8, 2026, with no clear company-specific announcement explaining the move. - Scheduled to...
🟢 Tenax Therapeutics is trading 5.4% up today; no company-specific announcement explains move
Tenax Therapeutics is trading 5.4% up at $2.04, based on live price context; no September 8, 2026 company-specific announcement explicitly explains the...
🟢 Tenax Therapeutics is trading 5.1% up today
Tenax Therapeutics is trading 5.1% up at $1.87, with no clear company-specific catalyst identified for the move. - The latest company announcement was a...
🟢 Tenax Therapeutics is trading 6.76% up today as XBI gains 2.75%
Tenax Therapeutics is trading $1.98 (+6.76%), with the advance appearing sector-driven rather than linked to a fresh company catalyst. - No new...
🟢 Tenax Therapeutics is trading 6% up today in pre-market
Tenax Therapeutics is trading at $1.96, up 5.95%, after closing at $1.85 on September 2, 2026, with no clear catalyst identified. - No new company-specific...
🟢 Tenax Therapeutics is trading 6% up today in after-hours trading with catalyst unclear
Tenax Therapeutics is trading 6% up at $1.97 after closing at $1.85 on September 2, 2026; the catalyst remains unclear, though provided price context shows a...
Tenax Therapeutics to Present at Cantor Healthcare Conference Following Key Trial Data Release
Tenax Therapeutics will participate in the 2026 Cantor Global Healthcare Conference. This follows the recent presentation of full results from its Phase 3...
🔴 Tenax Therapeutics is trading 14.08% down today after Guggenheim downgraded rating to Neutral
Tenax Therapeutics is trading 14.08% down at $1.83 after Guggenheim downgraded the stock from Buy to Neutral on August 31, 2026, citing uncertainty around...
🔴 Tenax Therapeutics is trading 9.87% down today after Guggenheim downgraded its rating to Neutral
Tenax Therapeutics is trading 9.87% down at $1.92 after Guggenheim downgraded its rating from Buy to Neutral on August 31, 2026, citing uncertainty around...
🟢 Tenax Therapeutics is trading 10.33% up in pre-market after LEVEL subgroup data showed improved exercise capacity
Tenax Therapeutics is trading 10.33% up at $2.35 after presenting detailed Phase 3 LEVEL results at the European Society of Cardiology Congress on August 29,...
Tenax's Heart Drug Missed the Big Test but Found a Promising Niche — Is That Enough to Justify the Bet?
Shares of Tenax Therapeutics jumped 9.4% to $2.33 after the company presented detailed data from its pivotal heart-drug trial at Europe's largest cardiology...
🟢 Tenax Therapeutics is trading 9.4% up in pre-market after subgroup showed 26.3-meter walking improvement
Tenax Therapeutics is trading 9.4% up now at $2.33 after additional Phase 3 LEVEL results were presented at the European Society of Cardiology Congress on...
Tenax Therapeutics Presents Full Phase 3 LEVEL Trial Data at ESC Congress 2026
Tenax Therapeutics presents full results from its Phase 3 LEVEL clinical trial for TNX-103 (oral levosimendan). The presentation occurs at the European Society...
Sphera Funds Management Discloses 5.33% Stake in Tenax Therapeutics
Sphera Funds Management disclosed a 5.33% passive stake in Tenax Therapeutics via a Schedule 13G filing with the SEC. Sphera and its affiliates beneficially...
🔴 Tenax Therapeutics is trading 6.47% down today — no clear negative catalyst identified
Tenax Therapeutics is trading 6.47% down now at $2.17, with no fresh company announcement or clearly documented negative catalyst identified for August 26. -...
Adar1 Bets $1.8 Million on Tenax After a Failed Drug Trial — Is Smart Money Seeing Something the Market Doesn't?
Shares of Tenax Therapeutics surged 17.6% to $2.17 after Adar1 Capital Management disclosed a major stock purchase just two weeks after the company's most...
🟢 Tenax Therapeutics is trading 17.57% up today after Adar1 Capital disclosed a $1.8 million share purchase
Tenax Therapeutics is trading 17.57% up at $2.17 after Adar1 Capital Management disclosed approximately $1.8 million in share purchases. - The investment firm...
Tenax Therapeutics jumps 13%, following $1.8 million Adar1 share purchase
Shares of Tenax Therapeutics rose nearly 13% in Tuesday's pre-market session. Adar1 Capital Management disclosed the purchase of over $1.8 million in company...